Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383290 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP3A4KDM4EMAPTCYP2C9 | |
| SCHEMBL11247306 | 0.90 | CYP1A2 (0.49) | CYP1A2CYP3A4KDM4EMAPTCYP2C9 | |
| SCHEMBL1922269 | 0.77 | CYP3A4 (0.76) | CYP1A2CYP3A4KDM4EMAPTCYP2C9 | |
| SCHEMBL29001503 | 0.75 | CYP1A2 (0.37) | CYP1A2PTPN11GRM5KCNH2CREBBP | |
| SCHEMBL29490274 | 0.75 | KCNH2 (0.43) | CYP1A2CYP3A4CYP2C19PTPN11GRM5 | |
| SCHEMBL28773588 | 0.75 | KCNH2 (0.38) | CYP1A2CYP3A4KDM4EMAPTALDH1A1 | |
| SCHEMBL21246857 | 0.75 | KCNH2 (0.43) | CYP1A2CYP3A4CYP2C19PTPN11GRM5 | |
| SCHEMBL28392107 | 0.75 | CYP3A4 (0.60) | CYP1A2CYP3A4KDM4EMAPTCYP2C9 | |
| SCHEMBL28356575 | 0.75 | HTR2C (0.46) | ALDH1A1MEN1KMT2AGRM5PTGES | |
| SCHEMBL31690840 | 0.73 | CYP1A2 (0.44) | CYP1A2KDM4EALDH1A1PTPN11GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| EP-2658844-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| WO-2012089633-A9 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012089633-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-07-05 | — | — | WO | disclosed |
| EP-1945206-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | Athersys, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007047775-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | TYMP, PIK3CA, PDPK1 | CYP1A2 3887/4885CYP3A4 2241/4885KDM4E 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.